Equities research analysts expect OncoSec Medical Incorporated (NASDAQ:ONCS) to post ($0.23) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for OncoSec Medical’s earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.24). OncoSec Medical reported earnings of ($0.39) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 41%. The firm is scheduled to report its next quarterly earnings report on Thursday, October 12th.

According to Zacks, analysts expect that OncoSec Medical will report full year earnings of ($1.05) per share for the current financial year, with EPS estimates ranging from ($1.14) to ($1.00). For the next financial year, analysts anticipate that the firm will report earnings of ($0.97) per share, with EPS estimates ranging from ($1.02) to ($0.91). Zacks’ EPS averages are an average based on a survey of research analysts that cover OncoSec Medical.

OncoSec Medical (NASDAQ:ONCS) last issued its earnings results on Thursday, June 1st. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.06.

A number of equities analysts have recently weighed in on the stock. ValuEngine raised shares of OncoSec Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, July 14th. Maxim Group set a $5.00 price target on shares of OncoSec Medical and gave the stock a “buy” rating in a research note on Saturday, June 3rd. HC Wainwright set a $6.00 price target on shares of OncoSec Medical and gave the stock a “buy” rating in a research note on Monday, June 12th. Dawson James reaffirmed a “buy” rating and issued a $5.00 price target on shares of OncoSec Medical in a research note on Thursday, July 6th. Finally, Noble Financial reaffirmed a “buy” rating on shares of OncoSec Medical in a research note on Wednesday, June 14th. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $5.33.

COPYRIGHT VIOLATION NOTICE: “OncoSec Medical Incorporated (NASDAQ:ONCS) Expected to Announce Earnings of -$0.23 Per Share” was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/08/03/oncosec-medical-incorporated-nasdaqoncs-expected-to-announce-earnings-of-0-23-per-share.html.

OncoSec Medical (ONCS) opened at 0.98 on Thursday. OncoSec Medical has a one year low of $0.88 and a one year high of $2.08. The firm’s market cap is $20.74 million. The company has a 50-day moving average price of $1.10 and a 200-day moving average price of $1.19.

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Get a free copy of the Zacks research report on OncoSec Medical (ONCS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.